LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer.
Authors:
- Kyoichi KairaKKKyoichi Kaira
- Noboru OriuchiNONoboru Oriuchi
- Toshiaki TakahashiTTToshiaki Takahashi
- Kazuo NakagawaKNKazuo Nakagawa
- Yasuhisa OhdeYOYasuhisa Ohde
- Takehiro OkumuraTOTakehiro Okumura
- Haruyasu MurakamiHMHaruyasu Murakami
- Takehito ShukuyaTSTakehito Shukuya
- Hirotsugu KenmotsuHKHirotsugu Kenmotsu
- Tateaki NaitoTateaki Naito
- Yoshikatsu KanaiYKYoshikatsu Kanai
- Masahiro EndoMEMasahiro Endo
- 7 October 2011
- journal article
- Vol. 3 (5) , 468-78
Abstract
L-type amino acid transporter 1 (LAT1) is known to be highly expressed in various human neoplasms. However, little is known about how LAT1 is associated with glucose metabolism, hypoxia and mammalian target of rapamycin (mTOR) signaling pathway in non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the relationship between LAT1 expression, and hypoxic marker and mTOR pathway in resected NSCLC. One hundred and sixty patients were included in this study. Tumors sections were stained by immunohistochemistry for LAT1, glucose transporter 1 (Glut1), hypoxia inducible factor-1α (HIF-1α), hexokinase I, vascular endothelial growth factor (VEGF), microvessel density (MVD) by determinate by CD34, epidermal growth factor receptor (EGFR), Phosphatase and tensin analog (PTEN), phosph-Akt, phosph-mTOR and phosph-S6K. A positive LAT1 and CD98 expression were recognized in 36.8% (59/160) and 33.7% (54/160), respectively (p=0.640). LAT1 expression was significantly associated with CD98, hypoxic markers (Glut1, HIF-1α, hexokinase I, VEGF and CD34) and mTOR pathway (EGFR, a loss of PTEN, p-mTOR and p-S6K), especially in lung adenocarcinoma (AC). The expression profile of these biomarkers was significantly higher in non-AC than in AC, but almost these biomarkers were equally expressed between AC (n=16) and non-AC (n=43) patients with a positive LAT1 expression. Overexpression of LAT1 was closely associated with poor outcome in patient with AC. LAT1 expression is closely correlated with hypoxic markers and mTOR pathway in patients with resected NSCLC.Keywords
This publication has 23 references indexed in Scilit:
- 4F2hc stabilizes GLUT1 protein and increases glucose transport activityAmerican Journal of Physiology-Cell Physiology, 2011
- Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: A possible target for combination therapy with anti-proliferative aminopeptidase inhibitorsBiochemical Pharmacology, 2010
- Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinomaLung Cancer, 2009
- CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node MetastasesAnnals of Surgical Oncology, 2009
- Correlation of angiogenesis with 18F‐FMT and 18F‐FDG uptake in non‐small cell lung cancerCancer Science, 2009
- Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancerBritish Journal of Cancer, 2008
- Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancerLung Cancer, 2008
- Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancerJournal of Clinical Pathology, 2005
- Hypoxia induces de‐stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cellsJournal of Neurochemistry, 2003
- Evidence for two Types of Mediation of Neutral Amino-Acid Transport in Ehrlich CellsNature, 1963